http://www.fool.com/investing/2017/01/11/more-innovation-less-regulation-3-biotech-stocks-t.aspx?
Trump's plan to tamp down the FDA's regulatory powers would be welcome news for this biopharma
Amarin is a small-cap Irish biopharma that sells the FDA-approved omega-3 medication Vascepa, indicated for patients with severely elevated triglyceride levels. The reason this stock is worth checking out right now is because Vascepa's tremendous commercial potential has undeniably been hampered by the FDA's current regulatory guidelines.
Since the drug's launch in 2013, for example, Vascepa has made respectable inroads into both the prescription omega-3 and non-statin prescription lipid therapy markets. But the drug still has a long way to go before it comes close to maxing out its commercial potential in either of these multi-billion dollar markets:
Vascepa Sales
Image Source: Amarin Corp.
The backstory is that the FDA initially rejected the drug's supplemental new drug application, which would have included patients with only moderately high triglycerides in its list of approved uses, which slowed its commercial uptake. After a lengthy court battle, Amarin eventually won the right to talk to doctors about off-label uses for Vascepa, but the company still has to stay within the strict bounds of the drug's FDA-vetted clinical dataset.
The point is that Trump's plan to turn the industry on its head from a regulatory standpoint could open the door for Amarin to market Vascepa broadly within the vast lipid therapy market, without even having to complete its ongoing cardiovascular outcomes trial.
If effectiveness isn't an issue, this DNA vaccine maker is grossly undervalued
Inovio Pharmaceuticals is striving to bring the first DNA-based vaccine or immunotherapy to market in the United States. The problem is that Inovio's platform, along with all other DNA vaccines to date, hasn't produced the type of clear cut effectiveness that warrants approval.
To get over this hurdle, Inovio has introduced novel delivery methods, such as the Cellectra 5PSP immunotherapy delivery device, and proposed the use of immune activators in conjunction with its DNA vaccines. However, the fact remains that this biotech has yet to advance even a single product candidate into late-stage development since its inception over 16 years ago, which certainly hasn't helped the performance of its share price:
INO Chart
INO data by YCharts
How could a Trump-directed FDA change Inovio's outlook? Inovio has completed a Phase 2 trial for its lead product candidate, VGX-3100, as a treatment for cervical dysplasia, where the vaccine produced a favorable safety profile and an intriguing efficacy signal.
So while it may sound outlandish to those who have watched the FDA repeatedly reject drugs with robust clinical programs, VGX-3100 may actually be good to go based on its Phase 2 safety data under a Trump administration.
The key is going to be Trump's ability to knock down the 1962 Kefauver-Harris Amendment requiring drug manufacturers to demonstrate experimental products to be both safe and effective prior to approval. After all, his administration appears keen to transition to a regulatory framework that favors "real world" evidence of a drug's effectiveness -- evidence that people like Jim O'Neill believe can be gathered after a drug is already on the market.
Here are 5 stocks that made it through this week's screen:
(AMRN - Free Report) Amarin Corp.
(CGEN - Free Report) Compugen
(RPTP - Free Report) Raptor Pharmaceuticals
(MT - Free Report) ArcelorMittal
(HOV - Free Report) Hovnanian Enterprises
I think each one of these picks has big potential. And the entire list is worth a thorough analysis.
I would not suggest filling up an entire portfolio of stocks under $10 though. But adding a careful selection of some of the best cheap stock names could add some excess returns to your bottom line, not to mention a little excitement to your stock picking process as well.
Get the rest of the stocks on this list and start screening for the best stocks under $10 for yourself. And don't forget to backtest your strategy so you'll know how successful it's been before you put any of your money at risk. You can do it.
https://www.zacks.com/commentary/89923/explosive-stocks-under-10
AMRN
Adam Russell
Adam graduated from UCL in 1998 with an honors degree in Business Finance (BSc). He has spent the last two decades identifying undervalued companies in US markets, primarily in the healthcare and insurance industries. Outside of the financial world,
Fianciero specializes in undervalued companies INTERESTING IN YOUR OPINION ON AmArin; undervalued companies.
AMRN
They are going to raise enough money to complete Reduce it. The funds buying the deal are probably working for one of the large pharma companies that will acquire Amarin soon. This is a good deal if you want to get in at a low price before any takeover is announced
